Shandong Weigao Group Medical Polymer Co (1066) AI Stock Analysis

• Market Cap: HK$28.26B
• Dividend Yield: 4.32%
• Average Volume (3M): 11.96M
• Price to Earnings (P/E): 12.7
• Beta (1Y): 1.04
• Revenue Growth: -3.09%
• EPS Growth: 0.67%
• Country: HK
• Employees: 12,719
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.23
• Shares Outstanding: 4,522,332,000
• 10 Day Avg. Volume: 6,487,027
• 30 Day Avg. Volume: 11,957,512
• PEG Ratio: 1.05
• Price to Book (P/B): 2.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 46.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$5.20
• Price Target Upside: -16.77% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 77 Outperform
• Price Target: HK$7.00 ▲(12.00%Upside)

The stock is rated favorably due to its strong technical performance and stable financials. The positive price trend and attractive valuation with a good dividend yield contribute to its appeal. However, the decline in revenue growth and incomplete cash flow data are areas that require attention.

Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model

Company Description

Shandong Weigao Group Medical Polymer Co., Ltd. (1066) is a leading manufacturer and distributor of medical devices and consumables based in China. The company operates primarily in the healthcare sector, focusing on the production of a wide range of medical products, including single-use medical devices, orthopedic materials, and blood purification equipment. Shandong Weigao Group is committed to providing high-quality and cost-effective medical solutions to healthcare providers and institutions globally.

How the Company Makes Money

Shandong Weigao Group Medical Polymer Co. makes money through the manufacture and sale of a diverse portfolio of medical products. Its key revenue streams include single-use medical devices such as syringes, infusion sets, and blood bags. Additionally, the company generates income from its orthopedic materials and blood purification equipment segments. The company benefits from strategic partnerships and collaborations with healthcare institutions, which help to expand its market reach and product offerings. Revenue is also driven by its strong distribution network and its ability to innovate and meet the growing demand for medical products both domestically and internationally.

Shandong Weigao Group Medical Polymer Co Financial Statement Overview

Summary

Shandong Weigao Group Medical Polymer Co demonstrates strong profitability and a stable financial position, with healthy margins and conservative leverage. However, the slight decline in revenue and the lack of detailed cash flow data for the latest year suggest areas for improvement, particularly in cash flow management and revenue growth.

Income Statement

The company shows strong profitability with a consistent gross profit margin around 50% and a stable net profit margin in the range of 15-20%. However, there has been a slight decline in revenue growth, with a negative growth rate of approximately -1.1% from the previous year. EBIT and EBITDA margins remain healthy, indicating efficient cost management.

Balance Sheet

The balance sheet reflects a stable financial position. The debt-to-equity ratio is low, suggesting prudent leverage, while the equity ratio indicates a strong equity base with around 68% of total assets financed by equity. Return on Equity (ROE) has been relatively stable, reflecting decent returns to shareholders.

Cash Flow

The company has shown positive free cash flow, though the free cash flow growth rate is unavailable for the latest year. The operating cash flow to net income ratio is not calculable due to missing operating cash flow data for the latest year, indicating potential cash flow management issues that need addressing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.09B	13.23B	13.62B	13.15B	11.35B
Gross Profit	6.58B	6.64B	7.11B	7.27B	6.46B
EBITDA	3.14B	3.55B	4.38B	3.75B	3.30B
Net Income	2.07B	2.00B	2.76B	2.28B	2.09B
Balance Sheet
Total Assets	34.76B	33.67B	33.20B	30.37B	27.34B
Cash, Cash Equivalents and Short-Term Investments	8.32B	7.33B	7.36B	7.06B	5.98B
Total Debt	4.19B	4.17B	4.49B	4.14B	4.32B
Total Liabilities	9.42B	9.68B	9.75B	9.46B	8.95B
Stockholders Equity	23.75B	22.45B	21.67B	19.27B	17.55B
Cash Flow
Free Cash Flow	2.14B	2.11B	1.10B	1.92B	1.70B
Operating Cash Flow	2.79B	2.80B	2.21B	3.04B	2.70B
Investing Cash Flow	-1.10B	-1.39B	-2.57B	-1.48B	423.22M
Financing Cash Flow	-1.60B	-2.16B	-1.02B	-538.08M	-1.79B

Shandong Weigao Group Medical Polymer Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1066, the sentiment is Positive. The current price of 6.25 is above the 20-day moving average (MA) of 6.05, above the 50-day MA of 5.81, and above the 200-day MA of 5.06, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 54.97 is Neutral, neither overbought nor oversold. The STOCH value of 69.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1066.

Shandong Weigao Group Medical Polymer Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9997	83 Outperform	€9.53B	15.05	18.36%	21.75%	7.13%	13.39%
1066	77 Outperform	HK$28.26B	12.66	8.95%	4.32%	-3.09%	0.67%
1358	76 Outperform	€2.01B	12.37	3.72%	4.24%	11.84%	-2.22%
3600	74 Outperform	HK$4.04B	9.98	15.04%	4.27%	6.05%	1.32%
2276	68 Neutral	HK$17.83B	33.35	28.81%	0.95%	14.99%	31.70%
1501	67 Neutral	HK$4.40B	19.76	11.24%	1.20%	11.23%	20.39%
Sector *	60 Neutral	HK$15.58B	5.65	-7.43%	4.32%	11.60%	-21.06%

Shandong Weigao Group Medical Polymer Co Corporate Events

Shandong Weigao Group Establishes Nomination Committee to Enhance Governance

Shandong Weigao Group Medical Polymer Company Limited has outlined the terms of reference for its Nomination Committee, which is responsible for reviewing the board’s structure and composition, identifying suitable director candidates, and making recommendations for board appointments and succession planning. This move is aimed at enhancing the company’s governance and aligning its board composition with its corporate strategy to promote shareholder value.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Announces Leadership Change

Shandong Weigao Group Medical Polymer Company Limited announced a change in its board leadership effective 28 May 2025. Mr. Tang Zhengpeng has resigned as Vice-Chairman but will continue his role as a non-executive Director and committee member. Ms. Yan Xia, previously a non-executive Director, will succeed him as Vice-Chairman. This leadership transition is part of the company’s strategic reassignment of duties and responsibilities, potentially impacting its governance and stakeholder relations.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Announces Board Composition

Shandong Weigao Group Medical Polymer Company Limited has announced the composition of its board of directors and their respective roles. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and operational oversight, which is crucial for stakeholders and investors.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Announces Final Dividend for 2024

Shandong Weigao Group Medical Polymer Co. has announced a final cash dividend of RMB 0.1235 per share for the financial year ending December 31, 2024, with shareholder approval scheduled for May 27, 2025. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.0888, with a payment date set for July 11, 2025. The announcement also details the withholding tax rates applicable to non-resident shareholders, with a 10% rate for enterprises and individuals outside China and a 20% rate for domestic individual investors using the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Announces Successful AGM and Dividend Payment

Shandong Weigao Group Medical Polymer Company Limited held its Annual General Meeting on 27 May 2025, where all proposed resolutions were successfully passed by poll. Key resolutions included the approval of the audited financial statements for 2024, the declaration of a final dividend, and the reappointment of Deloitte Touche Tohmatsu as the company’s auditor. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued stability and growth.

The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.

Shandong Weigao Group Makes Regulatory Announcement

Shandong Weigao Group Medical Polymer Company Limited has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement, which was also published on the Shanghai Stock Exchange’s website, highlights the company’s adherence to regulatory standards, potentially impacting its market positioning and stakeholder confidence positively.

Shandong Weigao Announces AGM with Key Resolutions

Shandong Weigao Group Medical Polymer Company Limited has announced its upcoming annual general meeting (AGM) scheduled for May 27, 2025. The AGM will address various resolutions, including the approval of the company’s audited financial statements for 2024, the declaration of a final dividend, re-appointment of auditors, and re-election of directors and supervisors. Additionally, a special resolution will consider granting the board a general mandate to issue and deal with shares. These resolutions are crucial for the company’s governance and strategic planning, potentially impacting its market positioning and shareholder value.